Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cantargia AB ( (SE:CANTA) ) has provided an announcement.
Cantargia AB will participate in TD Cowen’s 46th Annual Health Care Conference in Boston from March 2 to 4, 2026, where members of its management team will also host one‑on‑one meetings with investors and other stakeholders. The company’s presence at this major healthcare investor event underscores its efforts to raise visibility for its IL1RAP‑based antibody platform, including its lead cancer therapy nadunolimab and the value highlighted by last year’s sale of its CAN10 program to Otsuka Pharmaceutical, potentially supporting its positioning in the biotech and oncology investment community.
The most recent analyst rating on (SE:CANTA) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a Swedish biotechnology company focused on developing antibody-based treatments for life‑threatening diseases, leveraging a platform targeting the protein IL1RAP, which is implicated in various cancers and inflammatory conditions. Its lead oncology antibody, nadunolimab (CAN04), is in clinical studies mainly in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer, while its second program, CAN10, targeting serious autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025.
YTD Price Performance: 20.67%
Average Trading Volume: 3,629,182
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.26B
For an in-depth examination of CANTA stock, go to TipRanks’ Overview page.